Results 141 to 150 of about 1,505 (151)

NICE recommends ataluren for selected patients with MD

PharmacoEconomics & Outcomes News, 2016
openaire   +1 more source

Länger motorisch aktiv bei Duchenne-Muskeldystrophie mit Ataluren

Pädiatrie, 2023
openaire   +1 more source

Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry.

Journal of Comparative Effectiveness Research, 2019
Francesco Muntoni, Eugenio Mercuri, Janbernd Kirschner   +2 more
exaly  

Molecule of the month. Ataluren.

Drug news & perspectives, 2010
openaire   +1 more source

NICE issues final guidance recommending ataluren for DMD

PharmacoEconomics & Outcomes News, 2016
openaire   +1 more source

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2017
Craig Campbell, Ulrike Schara-Schmidt, Thomas Sejersen   +2 more
exaly  

Expert Opinion on Pharmacotherapy

Expert Opinion on Pharmacotherapy, 2017
Aaron Gardner, Iram J Haq, Malcolm Brodlie   +2 more
exaly  

NICE asks for more evidence to justify cost of ataluren

PharmacoEconomics & Outcomes News, 2015
openaire   +1 more source

CHMP recommends not renewing marketing authorisation for ataluren

Reactions Weekly
openaire   +1 more source

Ataluren for Duchenne: how politics and social pressure undermined evidence-based decisions

BMJ Evidence-Based Medicine
Juan Erviti, Luis Carlos Saiz, Marta Gutiérrez-Valencia   +2 more
openaire   +2 more sources